envudeucitinib: Clinical Trials

3 completed, 2 active not recruiting. 2 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	2	Active not recruiting 2
Phase 3	2	Completed 2
Phase 1	1	Completed 1

Follow envudeucitinib: new trials by email Literature Review of envudeucitinib trials Research Report on envudeucitinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage envudeucitinib - Hepatic Impairment	Phase 1	Completed	Alumis Inc	32	2025-04-29	2026-05-12
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Envudeucitinib, Placebo, Apremilast - Plaque Psoriasis	Phase 3	Completed	Alumis Inc	862	2024-08-20	2026-08-10
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis Envudeucitinib, Apremilast, Placebo - Plaque Psoriasis	Phase 3	Completed	Alumis Inc	912	2024-07-25	2026-08-10
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus Envudeucitinib, Placebo - SLE	Phase 2	Active not recruiting	Alumis Inc	408	2023-06-26	2026-07-21
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis envudeucitinib - Plaque Psoriasis	Phase 2	Active not recruiting	Alumis Inc	165	2023-01-17	2026-07-28

Conditions studied

Autoimmune Diseases (1)  ·  Connective Tissue Diseases (1)  ·  Immune System Diseases (1)  ·  Lupus Erythematosus, Systemic (1)

Sponsors

Alumis Inc (5)

Countries

United States (5)  ·  Canada (3)  ·  Germany (3)  ·  Poland (3)  ·  Bulgaria (2)  ·  Hungary (2)  ·  Puerto Rico (2)  ·  South Korea (2)  ·  Spain (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Chile (1)  ·  Colombia (1)  ·  Croatia (1)

Top investigators

Jorn Drappa, Medical Director (1)

Results publications

PMID 41061968